Figure S4 from RNA-encoded Interleukin 2 with Extended Bioavailability Amplifies RNA Vaccine–Induced Antitumor T-cell Immunity

Antitumor immunity in response to RNA-LPX and Alb-IL2 RNA-NP. Absolute number of vaccine antigen-specific and nonvaccine antigen-specific CD8⁺ T cells, Tregs, and NK cells in the tumor (n=6 mice/group; A), tumor-draining lymph node (n=6 mice/group; B), and spleen (Alb RNA-NP: n=5 mice/group; Alb-IL2 RNA-NP: n=6 mice/group; C) of CT26 tumor-bearing BALB/c mice 5 days after i.v. administration of gp70 RNA-LPX combined with Alb-IL2 RNA-NP or Alb RNA-NP on day 12 after tumor cell inoculation. Mean + SEM. Two-tailed Student t-test. *P≤0.05.